Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Fitzgerald, M. Whitmarsh, J. Prosser, A. Banyard, P. Lockey (Slough, Harlow, Manchester, United Kingdom). The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma. Eur Respir J 2013; 42: Suppl. 57, 735

Member's Comments

No comment yet.

Related content which might interest you: The safety, PK and PD profile of ADC3680, a potent and selective CRTh2 antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Pharmacological treatment of asthma today Source: Eur Respir J 2001; 18: 34S-40S Year: 2001 LATE-BREAKING ABSTRACT: GW870086: A potent anti-inflammatory glucocorticoid with a novel pharmacological profile Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 QAW039, a slowly dissociating CRTh2 antagonist with potential for improved clinical efficacy Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Safety profile and pharmacokinetics of an inhaled GATA-3-specific DNAzyme in a phase Ib study in patients with stable allergic asthma Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014